Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 57Carcinoma, Renal Cell 19Leukemia, Myeloid, Acute 15Lymphoma, Non-Hodgkin 10Leukemia 10Kidney Neoplasms 10Skin Neoplasms 9Neuroblastoma 9Neoplasms 9Neoplasm Metastasis 9Lymphoma 9Breast Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Congenital Abnormalities 5Uveal Melanoma 4Multiple Myeloma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Hematologic Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2

Interventions

Cisplatin 33Radiotherapy 23Cetuximab 18Paclitaxel 14Docetaxel 14pembrolizumab 13Carboplatin 12Fluorouracil 10Radiotherapy, Intensity-Modulated 8Nivolumab 8Drug Therapy 7Erlotinib Hydrochloride 6Panitumumab 5dacomitinib 4Radiation 4Methotrexate 4Esophagectomy 4130-nm albumin-bound paclitaxel 4durvalumab 3ON 01910 3Leucovorin 3Gemcitabine 3Chemoradiotherapy 3vandetanib 2palbociclib 2osimertinib 2nedaplatin 2fludarabine 2cabazitaxel 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Squamous Cell × Interleukin-2 × Clear all
NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
20 enrolled 10 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡